Volatility in the economy is causing digital health companies to rethink their strategies for the remainder of 2025.

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Korro Bio is laying off a fifth of its workforce as the Novo Nordisk-partnered biotech funnels resources to its ...

We expected miracles—what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Novo Nordisk (NVO) closed the last trading session at $67.55, gaining 3.8% over the past four weeks, but there could be ...

Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision to declare the end of the shortage of Novo Nordisk’s semaglutide, Judge ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

In a unique collaboration to raise awareness of haemophilia in Thailand, Danish healthcare company Novo Nordisk and Thai ...

City Hall chiefs point finger at poor work-life balance as stark health data emerges, prompting a new initiative to create a ...

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...

It was spurred by the Intercept’s disclosure of Musk’s hitherto-secret White House email address: [email protected]. When the Intercept first published Musk’s email address, on March 6, journalist ...

Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...